Switch to
More onapp

EVOQ Remedies Ltd

EVOQ
Trading
SmallcapWith a market cap of ₹18 cr, stock is ranked 3,279
High RiskStock is 4.92x as volatile as Nifty
13.750.25 (+1.85%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Trading
SmallcapWith a market cap of ₹18 cr, stock is ranked 3,279
High RiskStock is 4.92x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
17.88
PB RatioPB Ratio
0.83
Dividend YieldDiv. Yield
Sector PESector PE
-46.75
Sector PBSector PB
4.26
Sector Div YldSctr Div Yld
0.11%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

EVOQ Remedies Limited is engaged in the pharmaceutical business. The Company is engaged in marketing, trading, and distribution of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic and anti-cold drugs, analgesic/ antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, antioxidants, and injections. The Company also deals in the trading of active pharmaceutical ingredients (APIs). The Company's products include Abacavir Sulphate, Acetazolamide, Acyclovir, Adefovir Dipivoxil Allylestrenole, Alpha Beta Arteether, Alpha Lipoic Acid, Alprazolam, Amisulpride, Amoxycillin Trihydrate, Ampicillin Trihydrate, Artemether, Atracurium Besylate, Azathioprine, Azithromycin, Balofloxacin, Bendamustine, Biotin, Bosentan, Brimonidine, Bezafibrate Mupirocin, Mycophenolate, Mycophenolate, Nadifloxacin, Naltrexone HCL and more.

Financial TrendFinancial statements 

20192020202120223.259.0710.0216.780.010.000.711.08
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Hmm, looks like data is unavailable here. Please come back after some time
See all events